TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7919941
Drug: Haloperidol doses
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol doses greater than 100 mg/day
Study: 28566028
Drug: Forensic Assertive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forensic Assertive Community Treatment (FACT)
Study: 28832365
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment arm (SBP < 120 mmHg)
Study: 28832365
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (SBP < 140 mmHg)
Study: 23567785
Drug: Subglottic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subglottic and gastric treatment suspension (polymyxin E 100 mg, vancomycin 1 g, and amphotericin B 500 mg) + intravenous cefotaxime (1 g 3 times a day for 4 days)
Study: 23567785
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + intravenous cefotaxime (1 g 3 times a day for 4 days)
Study: 23567785
Drug: Subglottic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subglottic placebo and gastric treatment suspension + intravenous cefotaxime (1 g 3 times a day for 4 days)
Study: 23567785
Drug: Subglottic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subglottic treatment suspension and gastric placebo + intravenous cefotaxime (1 g 3 times a day for 4 days)
Study: 15006014
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (CRO) 20 mg
Study: 11491366
Drug: FSH/human menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH/human menopausal gonadotropin combination
Study: 8148352
Drug: Baseline diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline diet (36% kcal as fat: 15% saturated, 15% monounsaturated, and 6% polyunsaturated fat; 180 mg cholesterol.1000 kcal‐1)
Study: 31715584
Drug: Postexercise glucose-fructose
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexercise glucose-fructose coingestion (1.5 g·kg‐1·hr‐1 carbohydrate)
Study: 31715584
Drug: Postexercise glucose-fructose
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexercise glucose-fructose coingestion (1.2 g·kg‐1·hr‐1 carbohydrate)
Study: 21561959
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 200 mg/day for 8 weeks)
Study: 12595969
Drug: Steroid+ (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid+ (10 mg/day, n=17)
Study: 12595969
Drug: Steroid- (n=10)
Normalized name: 4-amino-N(10)-methylpteroylglutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid- (n=10)
Study: 9069450
Drug: Gemfibrozil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (300 to 900 mg/day)
Study: 29846686
Drug: No drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug-eluting sheet (control) group
Study: 24862977
Drug: PM(2.5) increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM(2.5) increase (7.0 µg/m³)
Study: 19423029
Drug: Debridement plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement plus topical antifungal nail lacquer
Study: 17374661
Drug: Egg treatment
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg treatment (640 mg/d additional cholesterol and 600 µg/d additional lutein + zeaxanthin)
Study: 17374661
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment (no additional cholesterol or lutein + zeaxanthin)
Study: 11476766
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (40 mg/d, p.o.)
Study: 9916606
Drug: Cefprozil 500
Normalized name: cefprozil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil 500 mg BID
Study: 9916606
Drug: Amoxicillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500 mg/125 mg TID
Study: 3054453
Drug: VP-16 plus
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VP-16 plus lower dose adriamycin (VAD)
Study: 31733813
Drug: Structured six-session
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured six-session psychological treatment
Study: 31733813
Drug: Routine antenatal
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antenatal health care and three monthly phone calls
Study: 28710902
Drug: Single-session cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session cognitive behavioural therapy intervention including a risk communication module
Study: 25789661
Drug: Idarucizumab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (doses between 20 mg and 8 g as a 1-hour intravenous infusion, or 1, 2 or 4 g as a 5-minute infusion)
Study: 19470877
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with Aml/Val/HCTZ 10/320/25 mg
Study: 19470877
Drug: Dual therapies
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapies (Val/HCTZ 320/25 mg, Aml/Val 10/320 mg, Aml/HCTZ 10/25 mg)
Study: 17407632
Drug: Intensive multi-injection
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive multi-injection protocol (two or four times daily regular/NPH insulin injections)
Study: 17407632
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily insulin injections
Study: 15379417
Drug: Leptin/adiponectin (L/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin/adiponectin (L/A) ratio in obese children
Study: 15379417
Drug: Leptin/adiponectin (L/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin/adiponectin (L/A) ratio in non-obese children
Study: 15204127
Drug: Multiple-choice task
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-choice task where participants selected possibilities indicating truth or falsity of compound verbal propositions.
Study: 7377911
Drug: Amitriptyline once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline once daily
Study: 7377911
Drug: Amitriptyline three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline three times daily
Study: 27621158
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to take daily probiotics (from October 2013 to March 2014)
Study: 27621158
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to take daily probiotics
Study: 20077490
Drug: Separate algorithm
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate algorithm for neo‐adjuvant chemotherapy‐treated tissues
Study: 12010236
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection therapy without sexological counselling (‐SC)
Study: 12010236
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection therapy with sexological counselling (+SC)
Study: 21434485
Drug: Ethanolic extract
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanolic extract of Ruta Chalepensis L. (250 microg/ml)
Study: 11203735
Drug: 0.025% capsaicin
Normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% capsaicin cream applied 4 times daily for 4 weeks
Study: 11203735
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle cream) applied 4 times daily for 4 weeks
Study: 18230389
Drug: Clobetasol 0.05%
Normalized name: CLOBETASOL 0.05% EMOLLIENT TOP CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol 0.05% ointment
Study: 8624625
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg once daily
Study: 1458892
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive containing 0.15 mg LNG and 0.03 mg EE2 (Microgynon)
Study: 1458892
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (Microgynon)
Study: 1458892
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of the same formulation
Study: 2935811
Drug: Prednisone-azathioprine-low dose
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prednisone-azathioprine-low dose cyclosporin A (8 mg/kg)
Study: 3422792
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus diflunisal (500 mg)
Study: 3422792
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus diflunisal (500 mg)
Study: 28646527
Drug: Dentalvibe® (DV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentalvibe® (DV) - buccal and palatal infiltration on the maxilla and inferior alveolar nerve block (IANB) with vibration
Study: 28646527
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method (TR) - same injections without vibration
Study: 20350952
Drug: ASA 500
Normalized name: ASA 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 500 mg/PSE 30 mg
Study: 20350952
Drug: ASA 1000
Normalized name: Canasa 1000mg Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 1000 mg/PSE 60 mg
Study: 20350952
Drug: APAP 1000
Normalized name: APAP 1000 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP 1000 mg/PSE 60 mg
Study: 18245404
Drug: Atomoxetine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.2 mg/kg per day)
Study: 1949926
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) dosing
Study: 6547808
Drug: Cookies with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cookies with 20 g of Fusarium graminearium
Study: 6547808
Drug: Cupcakes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupcakes with 10 g of Paecilomyces variotii
Study: 31732062
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup (40g, 14g of FOS)
Study: 29653651
Drug: 6F sheath/guide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6F sheath/guide combination
Study: 20642768
Drug: alpha-bisabolol-containing cream
Normalized name: alpha-bisabolol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-bisabolol-containing cream applied once a day for 8 weeks
Study: 20642768
Drug: vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle control cream
Study: 15791171
Drug: Methohexital alone
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital alone (80-100 mg IV bolus)
Study: 15791171
Drug: Remifentanil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (500 mcg IV bolus) with low-dose methohexital (40 mg IV)
Study: 9198431
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block + IO injection (2% lidocaine with 1:100,000 epinephrine)
Study: 9198431
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block (mock IO injection)
Study: 9198431
Drug: IO injection
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO injection
Study: 1761896
Drug: Rokitamycin (RKM)
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin (RKM) 600 mg daily for 5 days
Study: 1761896
Drug: Ofloxacin (OFLX)
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin (OFLX) 600 mg daily for 5 days
Study: 30803141
Drug: Intra-oral camera
Normalized name: Calmera Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral camera (IOC) + Text messages (TM)
Study: 29950229
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone + bortezomib + thalidomide (Group A)
Study: 29950229
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone + bortezomib + thalidomide (Group B)
Study: 26558356
Drug: IV‐PCA with
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV‐PCA with propacetamol (4 g)
Study: 26558356
Drug: IV‐PCA with
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV‐PCA with normal saline mixed to fentanyl (20 μg/kg)
Study: 25301463
Drug: Intravenous serelaxin
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous serelaxin for 48 hours
Study: 22707187
Drug: Zofenopril (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (60 mg/day) plus ASA (100 mg/day)
Study: 22707187
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg/day) plus ASA (100 mg/day)
Study: 20540652
Drug: pioglitazone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (15-30 mg/day) plus conventional oral hypoglycemic agents
Study: 20540652
Drug: conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional oral hypoglycemic agents alone
Study: 12450902
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplement
Study: 12450902
Drug: High-calcium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium diet (1300 mg/d)
Study: 12450902
Drug: Low-calcium diet
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium diet (300 mg/d)
Study: 22946966
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD) antibiotic prophylaxis with second-generation cephalosporin and metronidazole
Study: 22946966
Drug: Three-dose (MD)
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose (MD) antibiotic prophylaxis with second-generation cephalosporin and metronidazole
Study: 22946966
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD) antibiotic prophylaxis
Study: 22946966
Drug: Three-dose (MD)
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose (MD) antibiotic prophylaxis
Study: 18583047
Drug: Oral opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opioids (OP)
Study: 18583047
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NOP)
Study: 16646121
Drug: Computerized neuropsychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized neuropsychological rehabilitation (NR), 10-session adjunctive program
Study: 16646121
Drug: Standard substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard substance abuse treatment (no adjunctive NR)
Study: 14564328
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin combination (C+A)
Study: 11128566
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) and leucovorin (LCV) - dose intense regimen (biweekly)
Study: 11128566
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) and leucovorin (LCV) - standard regimen (monthly)
Study: 8844445
Drug: Procanbid (1,000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procanbid (1,000, 2,000, or 4,000 mg/day)
Study: 8844445
Drug: Procan SR
Normalized name: Procan SR
DrugBank: Procainamide (DB01035)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procan SR (1,000, 2,000, or 4,000 mg/day)
Study: 1470454
Drug: Sulfacetamide/prednisolone otic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfacetamide/prednisolone otic drops for 3 days postoperatively
Study: 29111902
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (240 mL daily)
Study: 29111902
Drug: Placebo (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (240 mL daily)
Study: 28383600
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection with 4% articaine and 1:100,000 epinephrine
Study: 24695100
Drug: Whole-body cryostimulation
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryostimulation (WBC) treatments, 30 treatments at -130°C for 3 minutes each
Study: 18564958
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music intervention (60 minutes for 15 sessions, 1 or 2 times weekly)
Study: 11915491
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (250 micrograms) with albuterol (0.15 mg/kg) - three nebulizations
Study: 11915491
Drug: Albuterol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (0.15 mg/kg) - six nebulizations (control group)
Study: 11915491
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (250 micrograms) with albuterol (0.15 mg/kg) - three nebulizations followed by three additional albuterol nebulizations
Study: 11915491
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide with albuterol in children less than six years of age
Study: 9440092
Drug: D-thyroxine 6
Normalized name: D-thyroxine
DrugBank: Dextrothyroxine (DB00509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-thyroxine 6 mg/d
Study: 2118299
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (angiography and angioplasty)
Study: 22526730
Drug: OROS-methylphenidate 72
Normalized name: methylphenidate hydrochloride 72 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-methylphenidate 72 mg daily for 5 weeks
Study: 22526730
Drug: OROS-methylphenidate flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-methylphenidate flexible dosage up to 1.3 mg/kg body weight during 47-week open-label extension
Study: 17690120
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mug daily
Study: 15070878
Drug: Gonadotrophin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin therapy
Study: 12048274
Drug: Trastuzumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab as adjuvant therapy
Study: 9032531
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day antibiotic prophylaxis (cefuroxime or ciprofloxacin)
Study: 9032531
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days antibiotic prophylaxis (cefuroxime or ciprofloxacin)
Study: 8497383
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone succinate (Solu-Medrol)
Study: 8497383
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg methylprednisolone succinate (Solu-Medrol)
Study: 3549319
Drug: Cyclosporin (Cy)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (Cy) administered for not more than 6 months at a maximum dosage of 10 mg/kg for 2 months
Study: 29573263
Drug: Pre-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intravenous (IV) methylprednisolone (MP) 125 mg
Study: 24472058
Drug: levocetirizine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: levocetirizine monotherapy
Study: 22249941
Drug: Alogliptin (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (12.5-25 mg/day)
Study: 16099227
Drug: Intermittent compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent compression therapy for 2 hours a day for 6 months
Study: 16099227
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g daily) and Vitamin D (800 IU daily)
Study: 14499318
Drug: haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 15 mg/day plus ethinyl estradiol 0.05 mg/day
Study: 11005607
Drug: Liposome-encapsulated 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome-encapsulated 1% clindamycin solution
Study: 11005607
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin solution (Klimicin T, Lek)
Study: 8610864
Drug: Dural puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dural puncture with a 26-gauge Whitacre spinal needle (no drug injected)
Study: 3324612
Drug: Oxycodone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone plus fentanyl
Study: 25300984
Drug: Gadobutrol (Gadavist)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobutrol (Gadavist) at a dose of 0.1 mmol/kg
Study: 25300984
Drug: Gadoteridol (ProHance)
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadoteridol (ProHance) at a dose of 0.1 mmol/kg
Study: 21701167
Drug: Omacor™ 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor™ 1 g/day (DHA/EPA ratio 1.25:1.0)